FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075215741> ?p ?o ?g. }

• W2075215741 endingPage "488" @default.
• W2075215741 startingPage "482" @default.
• W2075215741 abstract "The most effective agent for prophylaxis against venous thromboembolic disease after total joint arthroplasty (TJA) remains unknown. The paucity of literature comparing different methods of pulmonary embolism (PE) prophylaxis and fear of litigation make it difficult for surgeons to abandon the use of aggressive chemical prophylaxis. We compared the (1) overall frequency of symptomatic PE, (2) risk of symptomatic PE after propensity matching that adjusted for potentially confounding variables, and (3) other complications and length of stay before and after propensity matching in patients undergoing TJA at our institution who received either aspirin or warfarin prophylaxis. A total of 28,923 patients underwent TJA between January 2000 and June 2012 at our institution, had either aspirin (325 mg twice daily; 2800 patients) or warfarin prophylaxis (26,123 patients), and were registered in our institutional electronic database. The incidence of symptomatic PE, symptomatic deep vein thrombosis (DVT), hematoma formation, infection, wound complications, and mortality up to 90 days postoperatively was collected from the database. We performed multivariate analysis and 3:1 and 5:1 propensity score matching for comorbid and demographic variables. The overall symptomatic PE rate was lower (p < 0.001) in patients receiving aspirin (0.14%) than in the patients receiving warfarin (1.07%). This difference did not change after matching. The aspirin group also had significantly fewer symptomatic DVTs and wound-related problems and shorter hospital stays, which did not change after matching. After publication of the American Academy of Orthopaedic Surgeons’ guidelines, some surgeons have utilized aspirin as thromboprophylaxis after TJA. Based on our findings from a large institutional database, aspirin offers suitable prophylaxis against symptomatic PE in selected patients. Level III, therapeutic study. See Instructions for Authors for a complete description of levels of evidence." @default.
• W2075215741 created "2016-06-24" @default.
• W2075215741 creator A5027765716 @default.
• W2075215741 creator A5035412354 @default.
• W2075215741 creator A5038532275 @default.
• W2075215741 creator A5057218817 @default.
• W2075215741 creator A5076278772 @default.
• W2075215741 creator A5084270044 @default.
• W2075215741 date "2013-07-02" @default.
• W2075215741 modified "2023-10-05" @default.
• W2075215741 title "Aspirin: An Alternative for Pulmonary Embolism Prophylaxis After Arthroplasty?" @default.
• W2075215741 cites W1929354886 @default.
• W2075215741 cites W1964159013 @default.
• W2075215741 cites W1978105488 @default.
• W2075215741 cites W2000445173 @default.
• W2075215741 cites W2008317077 @default.
• W2075215741 cites W2009325026 @default.
• W2075215741 cites W2011327495 @default.
• W2075215741 cites W2011422601 @default.
• W2075215741 cites W2017909240 @default.
• W2075215741 cites W2020538743 @default.
• W2075215741 cites W2021058349 @default.
• W2075215741 cites W2022932023 @default.
• W2075215741 cites W2024237851 @default.
• W2075215741 cites W2029135270 @default.
• W2075215741 cites W2048313858 @default.
• W2075215741 cites W2049617241 @default.
• W2075215741 cites W2058252121 @default.
• W2075215741 cites W2062272588 @default.
• W2075215741 cites W2069378543 @default.
• W2075215741 cites W2069434842 @default.
• W2075215741 cites W2071058513 @default.
• W2075215741 cites W2097846523 @default.
• W2075215741 cites W2112391954 @default.
• W2075215741 cites W2123747749 @default.
• W2075215741 cites W2129168200 @default.
• W2075215741 cites W2154692607 @default.
• W2075215741 cites W2158953074 @default.
• W2075215741 cites W2162342763 @default.
• W2075215741 cites W2165088592 @default.
• W2075215741 cites W2166091057 @default.
• W2075215741 cites W2258503797 @default.
• W2075215741 cites W2335822722 @default.
• W2075215741 cites W2411897632 @default.
• W2075215741 cites W2475069216 @default.
• W2075215741 cites W3016782834 @default.
• W2075215741 cites W3026881396 @default.
• W2075215741 cites W3172077561 @default.
• W2075215741 cites W4322697031 @default.
• W2075215741 cites W83593494 @default.
• W2075215741 doi "https://doi.org/10.1007/s11999-013-3135-z" @default.
• W2075215741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3890197" @default.
• W2075215741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23817755" @default.
• W2075215741 hasPublicationYear "2013" @default.
• W2075215741 type Work @default.
• W2075215741 sameAs 2075215741 @default.
• W2075215741 citedByCount "85" @default.
• W2075215741 countsByYear W20752157412014 @default.
• W2075215741 countsByYear W20752157412015 @default.
• W2075215741 countsByYear W20752157412016 @default.
• W2075215741 countsByYear W20752157412017 @default.
• W2075215741 countsByYear W20752157412018 @default.
• W2075215741 countsByYear W20752157412019 @default.
• W2075215741 countsByYear W20752157412020 @default.
• W2075215741 countsByYear W20752157412021 @default.
• W2075215741 countsByYear W20752157412022 @default.
• W2075215741 countsByYear W20752157412023 @default.
• W2075215741 crossrefType "journal-article" @default.
• W2075215741 hasAuthorship W2075215741A5027765716 @default.
• W2075215741 hasAuthorship W2075215741A5035412354 @default.
• W2075215741 hasAuthorship W2075215741A5038532275 @default.
• W2075215741 hasAuthorship W2075215741A5057218817 @default.
• W2075215741 hasAuthorship W2075215741A5076278772 @default.
• W2075215741 hasAuthorship W2075215741A5084270044 @default.
• W2075215741 hasBestOaLocation W20752157412 @default.
• W2075215741 hasConcept C120665830 @default.
• W2075215741 hasConcept C121332964 @default.
• W2075215741 hasConcept C126322002 @default.
• W2075215741 hasConcept C141071460 @default.
• W2075215741 hasConcept C17923572 @default.
• W2075215741 hasConcept C2776265017 @default.
• W2075215741 hasConcept C2776301958 @default.
• W2075215741 hasConcept C2777628954 @default.
• W2075215741 hasConcept C2778336525 @default.
• W2075215741 hasConcept C2778959117 @default.
• W2075215741 hasConcept C2779161974 @default.
• W2075215741 hasConcept C2780011451 @default.
• W2075215741 hasConcept C2780868729 @default.
• W2075215741 hasConcept C61511704 @default.
• W2075215741 hasConcept C71924100 @default.
• W2075215741 hasConcept C77350462 @default.
• W2075215741 hasConceptScore W2075215741C120665830 @default.
• W2075215741 hasConceptScore W2075215741C121332964 @default.
• W2075215741 hasConceptScore W2075215741C126322002 @default.
• W2075215741 hasConceptScore W2075215741C141071460 @default.
• W2075215741 hasConceptScore W2075215741C17923572 @default.
• W2075215741 hasConceptScore W2075215741C2776265017 @default.
• W2075215741 hasConceptScore W2075215741C2776301958 @default.

• next